Saturday, January 28, 2023 | Back issues
Courthouse News Service Courthouse News Service

Lidoderm Antitrust

A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust class action in the drug makers’ favor, a federal judge has ruled.

SAN FRANCISCO – A drug maker that dropped its patent suit against makers of the pain patch Lidoderm and agreed to delay its generic version could have won its lawsuit, an “alternate injury in a but-for world” that precludes resolving a sprawling antitrust class action in the drug makers’ favor, a federal judge has ruled.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...